HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

AbbVie Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

AbbVie Intelligence Report

Generated from 32 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Aug 1, 2026

Confidence

Moderate Confidence · 72%

Evidence

148 items

Sources

22

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

AbbVie maintains an active intelligence profile across Immunology, Biosimilar, Infectious Disease, Antiviral, Neurology. 32 signals are linked with 1 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 72% across 3 tracked sources. Highest-priority development: Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions. Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for AbbVie; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. investigateJul 26, 2026

    FDA Updates Boxed Warnings for JAK Inhibitors Due to Serious Risks

    Immunology · JAK Inhibitors · opportunity score 154

    View detail
  2. regulatory

    Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA AP — EPYSQLI (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    IND Application Reporting: IND Safety Reports

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    Investigational New Drug (IND) Application

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA AP — NORVIR (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA Approves First Generics of Gilotrif (afatinib) Tablets

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA AP — KALETRA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 4452 with buyer quality 10 (Enterprise). Competitive pressure: Low. Portfolio impact: High. 1 investigate-priority signal warrant near-term portfolio review.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — EPYSQLI (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • IND Application Reporting: IND Safety Reports

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Investigational New Drug (IND) Application

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NORVIR (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Approves First Generics of Gilotrif (afatinib) Tablets

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — KALETRA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • IND Application Reporting: IND Safety Reports

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Investigational New Drug (IND) Application

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — KALETRA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NORVIR (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • April - June 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Updates Boxed Warnings for JAK Inhibitors Due to Serious Risks

    Immunology · JAK Inhibitors

  • FDA Accepts Supplement Application for SKYRIZI (Risankizumab) by AbbVie

    Immunology · IL-23

  • FDA Accepts Supplement for ILUMYA (Tildrakizumab) by Sun Pharma

    Immunology · IL-23

  • AbbVie Initiates Phase 2b/3 Trial of Surabgene Lomparvovec for Diabetic Retinopathy

    Ophthalmology · Gene Therapy

  • AbbVie Initiates Study on Surzetoclax for Relapsed/Refractory Multiple Myeloma

    Oncology · Multiple Myeloma

  • FDA Grants Priority Review for ABBVIE's BLA761460 (DECNUPAZ)

    Oncology · Monoclonal Antibody

  • FDA Accepts Supplemental NDA for Linzess by AbbVie

    Gastroenterology · IBS-C

  • FDA Approves Supplemental Application for RINVOQ LQ by AbbVie

    Immunology · JAK Inhibitor

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.